Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2021 Financial Results and Webcast/Conference Call

Rhea-AI Summary

Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company, announced it will release its financial results for Q4 and full year 2021 on March 23, 2022, after market close. A webcast will follow at 4:30 p.m. ET for discussion of results and corporate updates. Celcuity's mission focuses on extending cancer patients' lives through an integrated therapeutic and diagnostic approach. The CELsignia diagnostic platform uniquely identifies suitable patient groups for existing targeted therapies.

Positive

• Announcement of financial results release date for Q4 and full year 2021, indicating transparency.
• Focus on integrated therapeutic and companion diagnostic strategy, highlighting innovation in cancer treatment.

Negative

• None.

MINNEAPOLIS, MN / ACCESSWIRE / March 16, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, today announced that it will release its financial results for the fourth quarter and full year 2021 after the stock market close on Wednesday, March 23, 2022. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

Webcast and Conference Call Information
To participate in the teleconference, domestic callers should dial 1-877-407-0784 and international callers should dial 1-201-689-8560 and reference conference ID: 13727768. A live webcast presentation can also be accessed using this weblink: https://viavid.webcasts.com/starthere.jsp?ei=1535102&tp_key=d9da71b7fd. A replay of the webcast will be available on the Celcuity website following the live event.

About Celcuity
Celcuity is a clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated therapeutic and companion diagnostic strategy. The company's therapeutic efforts are focused on in-licensing and developing molecularly targeted therapies that address the same cancer driver its companion diagnostics can identify. Its CELsignia companion diagnostic platform is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from already approved targeted therapies. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com.

Contacts:
Celcuity Inc.
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com
763-392-0123

ICR Westwicke
Robert Uhl, robert.uhl@westwicke.com
(619) 228-5886

SOURCE: Celcuity Inc.

View source version on accesswire.com:
https://www.accesswire.com/693244/Celcuity-Inc-Schedules-Release-of-Fourth-Quarter-and-Full-Year-2021-Financial-Results-and-WebcastConference-Call

FAQ

When will Celcuity release its financial results?

Celcuity will release its financial results for Q4 and full year 2021 on March 23, 2022.

What time is the webcast for Celcuity's financial results?

The webcast will be held at 4:30 p.m. Eastern Time on March 23, 2022.

What is the significance of Celcuity's CELsignia platform?

The CELsignia platform analyzes live tumor cells to identify cancer patients likely to benefit from existing targeted therapies.

What is the stock symbol for Celcuity?

Celcuity's stock symbol is CELC.